Scotiabank Reiterates Sector Outperform Rating on Myriad Genetics (MYGN)

October 14, 2024 10:25 AM UTC Send to a Friend
Scotiabank analyst Sung Ji Nam reiterated a Sector Outperform rating and $34.00 price target on Myriad Genetics (NASDAQ: MYGN).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login